Michel Manika Muteya | Microbial Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Michel Manika Muteya | Microbial Cell Biology | Best Researcher Award

Dr. Michel Manika Muteya, Faculty of Medicine, University of Lubumbashi, Congo, Democratic Republic of the

Dr. Michel Manika Muteya is a seasoned Congolese physician, specializing in Anesthesiology, Intensive Care, and Emergency Medicine. Born in Lubumbashi on September 5, 1972, he has dedicated over two decades to both clinical excellence and academic research. As Head of the Anaesthesiology-Intensive Care Department at the University Teaching Hospital of Lubumbashi since 2013, Dr. Muteya is recognized for advancing critical care practices in resource-limited settings. His scientific contributions, spanning over 20 peer-reviewed publications, tackle pressing health issues like sepsis, tuberculosis, transfusion medicine, and maternal care. A married father of five, he balances his demanding career with strong family values. With a collaborative spirit and global engagements, he contributes to large-scale studies including the ASOS-2 Lancet Trial, reflecting his impact in African surgical safety. His leadership and evidence-based approach make him a top contender for the Best Researcher Award.

Publication Profile: 

Orcid

Education:

Dr. Michel Muteya Manika received his Doctor of Medicine (MD) degree after completing an intensive medical program that included a year-long rotating internship (2003–2004) at Sendwe Hospital in Lubumbashi, covering internal medicine, pediatrics, surgery, and gynecology. He further honed his skills through a professionalization internship in General Medicine at the Ruashi Military Hospital (HMR) from November 2004 to May 2005. His specialization journey led him into the field of Anesthesiology and Intensive Care, where he developed key competencies in transfusion medicine, disaster medicine, and emergency response. In parallel, he has continually upgraded his academic profile by engaging in international conferences, research collaborations, and multi-country studies. His educational path reflects a strong clinical foundation coupled with academic curiosity, enabling him to bridge practical medicine with impactful research in sub-Saharan Africa.

Experience:

Dr. Michel Manika Muteya has served as the Head of Anaesthesiology and Intensive Care at the University Teaching Hospital of Lubumbashi since 2013. His leadership has driven improved patient outcomes and department-wide protocols, especially for sepsis, trauma, obstetric emergencies, and postoperative care. His hands-on training began with internships in internal medicine, pediatrics, surgery, and gynecology, followed by a professionalization period at a military hospital. With more than 20 years of clinical and academic experience, Dr. Muteya has also contributed to policy and training reforms in anesthesia education, collaborating with international teams in Rwanda and beyond. He’s a mentor, educator, and published researcher, involved in critical studies related to infectious diseases, HIV, malaria, and emergency care readiness. His commitment to healthcare in resource-limited environments underlines his passion for equitable, safe, and effective care, making his career a beacon of medical excellence in Central Africa.

Research Focus:

Dr. Michel Muteya Manika’s research primarily focuses on critical care medicine in low-resource settings, with specific interests in sepsis management, transfusion medicine, anesthetic safety, and infectious diseases such as tuberculosis and HIV. He investigates both the clinical and epidemiological aspects of disease patterns in the Democratic Republic of Congo, often exploring how infrastructure limitations affect care outcomes. His work extends to maternal and pediatric emergencies, post-operative surveillance, and clinical education reform, including developing curricula for anesthesiology clerkships in Africa. He collaborates widely across disciplines and borders, contributing to high-impact journals like The Lancet Global Health, BMC Health Services Research, and Pan African Medical Journal. A champion of evidence-based practice, Dr. Muteya seeks to align global standards with local realities, enhancing emergency response systems and training the next generation of African clinicians. His applied, context-specific research offers real-world solutions to systemic healthcare challenges.

Publications Top Notes: 

  1.  Prognosis of Tetanus Patients in ICU – Sendwe Hospital, Lubumbashi

  2.  Epidermoid Carcinoma of the Vulva in Twin Pregnancy – Case Report

  3.  Tuberculosis Revealed by Thrombocytopenic Purpura in a Child

  4.  Anemias in Pediatric Emergencies – 632 Cases Study

  5.  Peripheral Lymphadenopathy: Tertiary Center Study

  6.  Cytopathological Profile of Lymphadenopathies – 13 Cases

  7.  Malaria/HIV Coinfection Profile in Lubumbashi Adults

  8.  Seroprevalence of Blood Donors – University Clinics of Lubumbashi

  9.  Tuberculosis Profile in Lubumbashi Health Zone

  10.  Anesthesia Practices in Lubumbashi – Patient and Surgery Types

Conclusion:

Dr. Michel Manika Muteya is highly suitable for the Best Researcher Award. He combines clinical leadership, regional relevance, and consistent academic output in fields critical to healthcare improvement in Africa. His research addresses real-world health crises—sepsis, HIV, TB, surgical safety—through practical, evidence-based approaches. With a balance of hands-on expertise and scholarly excellence, he represents the ideal candidate whose work has both academic rigor and societal impact. Minor expansions in global visibility and technological integration would elevate his already impressive career to even greater heights.

Guannan Ma | Microbial Cell Biology | Best Researcher Award

Published on by Cell Biologist

Ms. Guannan Ma | Microbial Cell Biology | Best Researcher Award

Ms. Guannan Ma , Zhejiang Key Laboratory of Digital Technology in Medical Diagnostics , China

Guannan Ma is a seasoned biomedical researcher and medical manager based in Beijing, China, with over a decade of experience in molecular biology, genomics, and clinical research. He currently works at DIAN Gene Co., Ltd., where he leads clinical research projects, scientific writing, and patent development. With a strong academic foundation and a passion for translational medicine, he bridges laboratory research and real-world applications in diagnostics and therapeutics. His background includes extensive collaboration with national R&D initiatives and hospital systems, reflecting his ability to manage interdisciplinary projects and mentor junior scientists. Guannan is the co-author of over 15 peer-reviewed SCI papers and multiple patents in the fields of gene editing, DNA data storage, and cancer biology. Fluent in both English and Chinese, he is also certified in Good Clinical Practice (GCP), ensuring ethical and high-quality research standards. His contributions mark him as a strong contender for the Best Researcher Award.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. 📚 Extensive Publication Record

    • Over 15 SCI-indexed publications in top-tier journals such as Redox Biology, Advanced Science, and Genomics Proteomics Bioinformatics with a cumulative impact factor exceeding 60.

  2. 🔬 Interdisciplinary Research Expertise

    • Proven proficiency in multi-omics, CRISPR, genetic engineering, clinical research, and data analysis. His work spans microbiology, genomics, and translational medicine.

  3. 💡 Innovation & Intellectual Property

    • Multiple patents, including breakthrough innovations in DNA storage and cancer biomarker regulation, highlighting strong translational value and originality.

  4. 🌍 International and National Project Leadership

    • Key contributor to national R&D projects (e.g., DNA storage, microbiota gene adaptation) and cross-institutional collaborations.

  5. 📈 Clinical Impact & GCP Certification

    • Designs and executes clinical research supporting product development, demonstrating clear real-world applications.

  6. 👥 Mentorship and Team Leadership

    • Has supervised students, trained staff, and coordinated multicenter studies—showing strong leadership and collaborative aptitude.

🛠 Areas for Improvement:

  1. 🌐 Broader International Exposure

    • While Guannan has studied abroad, further global collaborations or fellowships (e.g., Horizon Europe, NIH, or WHO research programs) could enhance his international recognition.

  2. 📣 Science Communication & Outreach

    • Increasing science communication efforts (e.g., webinars, social media, TEDx talks) would help raise visibility of his research beyond academic audiences.

  3. 🔄 Continuous Skill Upgrading

    • Pursuing cutting-edge training in AI-based bioinformatics or clinical trial informatics could keep his expertise aligned with rapidly evolving biomedical tools.

🎓 Education:

Guannan Ma holds a Master of Science degree in Marine Science and Engineering from Tianjin University of Science and Technology (2012–2015), complemented by a year as a visiting Master’s student at Ghent University, Belgium (2014–2015). This dual exposure to domestic and international academic environments provided him with a robust interdisciplinary foundation. At Tianjin University, he developed a solid grasp of molecular biology, environmental genomics, and research methodologies, while his time at Ghent University enriched his perspective on global scientific standards and collaborative innovation. These academic experiences not only honed his technical expertise but also shaped his strong commitment to academic excellence and scientific rigor. His education played a crucial role in shaping his current research path, which integrates cutting-edge biotechnology, clinical research, and bioinformatics, and laid the groundwork for his involvement in high-impact national and international scientific projects.

💼 Experience:

Guannan Ma brings 10 years of diverse research and clinical project experience. Currently, as Medical Manager at DIAN Gene Co., Ltd. (since June 2022), he leads clinical study design, publication development, academic training, and patent filing. Prior to this, he spent over seven years (2015–2022) at the Beijing Institute of Genomics, Chinese Academy of Sciences, where he contributed to national research grants, supervised students, and mastered technologies like CRISPR-Cas9, ELISA, and mouse modeling. His work also included managing large-scale omics data and integrating microbiome, genetic, and metabolomic research. Across both roles, Guannan has demonstrated exceptional project leadership, technical fluency, and collaborative engagement across multi-disciplinary teams. His work has resulted in 15 high-impact SCI publications and multiple innovations in molecular diagnostics, microbial resistance, and gene therapy. With deep roots in both academia and industry, he exemplifies a rare blend of scientific depth, clinical insight, and leadership potential.

🔬 Research Focus:

Guannan Ma’s research focuses on the intersection of molecular biology, genomics, microbiome science, and clinical translation. His core areas include multi-omics data integration (genomics, transcriptomics, and metabolomics), gene editing (CRISPR-Cas9), and the development of diagnostic tools using advanced sequencing technologies such as Nanopore. He is particularly interested in antimicrobial resistance, host-pathogen interactions, and precision medicine strategies for diseases like cancer and infectious disorders. His recent contributions at DIAN Gene Co., Ltd. include initiating and leading clinical trials to support product indications, conducting systematic literature reviews, and ensuring the scientific integrity of marketing content. Guannan’s patent portfolio spans DNA data storage systems and microRNA-mediated cancer pathways, reflecting his commitment to high-impact innovation. He also supports scientific communication through English/Chinese academic writing and staff training. His work bridges scientific discovery and clinical application, driving forward patient-centered solutions rooted in cutting-edge genomics and biotechnology.

📚 Publications Top Notes:

  1. 🧫 Redox imbalance in disease: Role of redox biology in clinical research – Redox Biology, 2024

  2. 👶 Exploring biomarkers in pediatric diagnostics – Frontiers in Pediatrics, 2025

  3. 💊 Pharmacogenomics in personalized medicine – Pharmacogenomics and Personalized Medicine, 2024

  4. 🧪 Nanomaterials and biomedical advancements – Advanced Science, 2024

  5. 🦠 Candida auris strain characterization from bloodstream infections – Clinics, 2024

  6. 🧬 Probiotics in elderly pneumonia patients: Gut flora insights – Medicine, 2023

  7. 🔍 Digital twin systems for high-precision optical engineering – Preprints.org, 2023

  8. 🎵 Music therapy effectiveness in ASD children: Meta-analysis – Frontiers in Psychiatry, 2022

  9. 💾 DNA data storage: Encoding-decoding techniques overview – CCF Trans. on High Performance Computing, 2022

  10. 🧫 Genomic epidemiology of resistant Klebsiella pneumoniae strains – Genomics Proteomics Bioinformatics, 2022

🧾 Conclusion:

Guannan Ma is an exceptionally strong candidate for the Best Researcher Award. His balanced combination of scientific depth, innovation, and applied clinical relevance stands out. With a publication history that demonstrates both quality and breadth, contributions to national innovation priorities, and a proven track record of mentorship and teamwork, he embodies the qualities of a high-impact, future-forward researcher. By extending his global footprint and amplifying public engagement, Guannan Ma has the potential to become a key thought leader in life sciences and medical biotechnology.

Romain Villéger | Host-bacteria interactions | Cell Metabolism Award

Published on by Cell Biologist

Assist. Prof. Dr. Romain Villéger | Host-bacteria interactions | Cell Metabolism Award

Assist. Prof. Dr. Romain Villéger , Université de Poitiers , France

Dr. Romain Villéger is an Assistant Professor at the University of Poitiers, France, in the Ecology & Biology of Interactions (EBI) lab, within the Microorganisms-Hosts-Environments (MHE) team. With a Ph.D. from the University of Limoges, his work explores the intricate interactions between probiotics and host cells. He has held postdoctoral positions at the University of Bordeaux and the University of Texas Medical Branch, USA, focusing on microbiota-host relationships and metabolomics. Dr. Villéger’s research aims to unravel the role of bacterial interactions, particularly in the context of gastrointestinal health, microbiota, and cancer. His research has led to significant advancements in understanding microbial pathogenesis, including the effects of probiotics and endocrine disruptors on host cell metabolism. A dedicated researcher, he has contributed to numerous scientific publications and currently leads several high-impact projects on bacteria-host interactions.

Publication Profile:

Scopus

Strengths for the Award:

  1. Expertise in Metabolomics: Dr. Romain Villéger’s extensive work in metabolomics, especially in the context of host-bacteria interactions, positions him as a strong candidate for the Cell Metabolism Award. His research on bacterial influence on host cellular metabolism and gut microbiota interactions contributes significantly to the field of cellular metabolism.
  2. Innovative Research Contributions: His research, particularly on the metabolic changes during amoeba-Legionella interactions, showcases a novel approach to understanding microbial pathogenesis. By identifying metabolic vulnerabilities in pathogens, his work has the potential for therapeutic applications, thus addressing fundamental questions in cell metabolism.
  3. Multidisciplinary Approach: Dr. Villéger combines microbiology, immunology, and metabolomics, which enriches his contributions to cellular metabolism. His research is collaborative, evidenced by numerous projects across different institutions and fields, indicating a broad and innovative approach to the subject.
  4. Publications and Impact: He has a strong publication record, with numerous articles in peer-reviewed journals (19 publications), with high visibility in top-tier journals such as British Journal of Cancer, Frontiers in Cellular and Infection Microbiology, and Environmental Microbiology Reports. This demonstrates his influence and impact in the scientific community.
  5. Research Leadership: As the principal investigator of multiple projects, including those on the effects of phthalates on gut microbiota and cancer development, Dr. Villéger has demonstrated leadership in advancing scientific knowledge in areas that intersect with cell metabolism, host-microbe interactions, and metabolic changes in disease.

Areas for Improvement:

  1. Broader Clinical Translation: While his research shows deep insights into fundamental mechanisms, further work on translating these findings into practical clinical applications or therapeutic interventions would strengthen his impact in applied cellular metabolism.
  2. Interdisciplinary Team Development: While Dr. Villéger collaborates with many renowned researchers, fostering additional interdisciplinary partnerships could enrich his research by incorporating diverse techniques and perspectives from fields like drug development or personalized medicine.
  3. Expanding Metabolomic Toolkits: His research could benefit from exploring emerging and cutting-edge techniques in metabolomics, like single-cell analysis or multi-omics approaches, to gain deeper insights into cellular metabolism at the individual cell level.

Education:

Dr. Villéger completed his Ph.D. at the University of Limoges, where his thesis focused on the interactions between probiotics and host cells. His postdoctoral work spans institutions in France, the USA, and beyond, each contributing valuable insights into microbial-host dynamics and cellular microbiology. At the University of Bordeaux, he developed metabolomic approaches using GC/MS to study microbiota interactions. Later, at the University of Texas Medical Branch, he delved deeper into the effects of probiotics on intestinal homeostasis. Further postdoctoral experiences at the University of Clermont Auvergne involved examining the relationship between E. coli and colorectal cancer. Through these experiences, Dr. Villéger has gained expertise in microbiota research, cell biology, and metabolic analysis, providing a foundation for his ongoing work in the field. His education has provided a strong interdisciplinary framework, integrating microbiology, molecular biology, and toxicology into his research.

Experience:

Dr. Villéger has accumulated extensive experience in both academic and research settings. After earning his Ph.D. in 2014, he completed several postdoctoral positions, with notable work at the University of Bordeaux, where he pioneered metabolomics techniques for microbiota research. His tenure at the University of Texas Medical Branch expanded his focus to the effects of probiotics on intestinal homeostasis. Additionally, his work at the University of Clermont Auvergne involved exploring the connection between microbial interactions and cancer. Since joining the University of Poitiers in 2020 as an Assistant Professor, Dr. Villéger has led several research projects, including investigating the impact of endocrine disruptors on colorectal cancer development. He is also a leader in metabolomics and microbial pathogenesis, with a particular focus on bacteria-host interactions and microbiota modulation. His research has contributed to numerous publications and collaborations with institutions worldwide, showcasing his ability to manage complex research projects.

Research Focus:

Dr. Villéger’s research primarily focuses on bacteria-host interactions, gut microbiota, and cellular microbiology, with a special interest in how microbial populations affect host metabolism. His work integrates metabolomics, a powerful tool for studying metabolic processes, to better understand microbial influence on host cells. Dr. Villéger’s recent studies explore the role of oxidative stress in microbial infections, including Legionella pneumophila’s subversion of host immune defenses during infection. He has also investigated the impact of endocrine disruptors on microbial virulence, providing insights into the potential links between environmental factors and microbial pathogenesis. His contributions to understanding the microbiota-gut-brain axis, particularly in the context of colorectal cancer, emphasize the metabolic changes induced by bacterial interactions. Dr. Villéger’s research aims to identify biomarkers for disease and therapeutic interventions, with a broader goal of advancing precision medicine through a better understanding of the cellular and metabolic processes that underlie microbial-host dynamics.

Publications Top Notes:

  1. Legionella pneumophila subverts the antioxidant defenses of its amoeba host Acanthamoeba castellanii 💥🦠
  2. Increased Activity of MAPKAPK2 within Mesenchymal Cells as a Target for Inflammation-Associated Fibrosis in Crohn’s Disease 🔬🧬
  3. Exposure to endocrine disruptors promotes biofilm formation and contributes to increased virulence of Pseudomonas aeruginosa 💧🦠
  4. Loss of alcohol dehydrogenase 1B in cancer-associated fibroblasts: contribution to the increase of tumor-promoting IL-6 in colon cancer 🧬🦠
  5. Effect of endocrine disruptors on bacterial virulence 🌿🧪
  6. Proteomic analysis of Acanthamoeba castellanii response to Legionella pneumophila infection 🔬🦠
  7. Disruption of retinol-mediated IL-6 expression in colon cancer-associated fibroblasts: new perspectives on the role of vitamin A metabolism 🧬🍊
  8. Microbiota medicine: towards clinical revolution 🌍💊
  9. Deletion of cystathionine-γ-lyase in bone marrow-derived cells promotes colitis-associated carcinogenesis 🔬🦠
  10. Prebiotic Isomaltooligosaccharide Provides an Advantageous Fitness to the Probiotic Bacillus subtilis CU1 🍞🦠

Conclusion:

Dr. Romain Villéger is a highly qualified candidate for the Cell Metabolism Award. His research contributions in understanding microbial influence on cellular metabolism and gut health, combined with his innovative approach to metabolomics, make him stand out in the field. His work bridges basic science and potential clinical applications, positioning him as a key figure in the ongoing exploration of microbial and metabolic influences on host physiology. With some expansion into clinical applications and further exploration of new metabolomics techniques, his contributions could significantly impact both scientific knowledge and medical practice.